These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. OSE Immunotherapeutics Sylvie Détry Sylvie.detry@ose-immuno.com +33 153 198 757 French Media: FP2COM Florence Portejoie fportejoie@fp2com.fr +33 607 768 283

Click and follow us on Twitter and Linkedln, https://twitter.com/OSEIMMUNOhttps://www.linkedin.com/company/10929673. Secondary endpoints include measures of pharmacokinetics, pharmacodynamics and immunogenicity to help assess and understand how the drug is absorbed and metabolized.

These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

Such forward-looking statements are not guarantees of future performance. :+33 (0) 1 43 29 78 57Fax : +33 (0) 1 42 03 04 16. IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel diseaseLyssia Belarif,1 Richard Danger,2,3 Laetitia Kermarrec,4 Véronique Nerrière-Daguin,2,3 Sabrina Pengam,1 Tony Durand,4 Caroline Mary,1 Elise Kerdreux,5 Vanessa Gauttier,1 Aneta Kucik,6 Virginie Thepenier,1 Jerome C. Martin,7,8,9 Christie Chang,7,8,9  Adeeb Rahman,7,10,11 Nina Salabert-Le Guen,2,12,13,14 Cécile Braudeau,2,12,13 Ahmed Abidi,2,15 Grégoire David,4 Florent Malard,2 Celine Takoudju,4 Bernard Martinet,2,3 Nathalie Gérard,2,3 Isabelle Neveu,4,5 Michel Neunlist,4,5 Emmanuel Coron,4,5 Thomas T. MacDonald,6 Pierre Desreumaux,16 Hoa-Le Mai,2,3 Stephanie Le Bas-Bernardet,2,3 Jean-François Mosnier,2,17 Miriam Merad,7,8,9,11 Régis Josien,2,3,12,14 Sophie Brouard,2,3 Jean-Paul Soulillou,2 Gilles Blancho,2,3 Arnaud Bourreille,4,5 Philippe Naveilhan,4,5 Bernard Vanhove,1 and Nicolas Poirier11OSE Immunotherapeutics, Nantes, France.

The new patent will cover OSE-127 through 2035, https://www.linkedin.com/company/10929673. BiCKI® is a bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) and targeting innovative targets.

In patients with active mucosal lesions, the overexpression of IL-7R, the target of OSE-127, is significantly increased and is predictive for non-response to anti-TNFα treatment.

OSE-127 is currently under Phase 1 clinical trial. The company has a diversified first-in-class clinical portfolio consisting of several scientific and technological platforms including neoepitopes and agonist or antagonist monoclonal antibodies, all ideally positioned to fight cancer and autoimmune diseases. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. Such forward-looking statements are not guarantees of future performance. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics.

BI 765063 (OSE-172) (anti-SIRPa monoclonal antibody) is under a license and collaboration agreement with Boehringer Ingelheim ; this checkpoint inhibitor has received CTA from French and Belgian health authorities for a Phase 1 clinical trial in multiple cancer indications. They do not constitute historical facts. This first notice of allowance in the U.S. is a major step in strengthening the product’s protection and should facilitate the grant of additional patents in other major territories covered by the same patent family.

NANTES, France, April 11, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), today announced the publication of data on OSE -127, its full-antagonist monoclonal antibody targeting the interleukin-7 receptor (IL-7R), in the prestigious Journal of Clinical Investigation (JCI).

The blockage of IL-7R prevents the migration of pathogenic T lymphocytes while preserving regulator T lymphocytes ) which have a positive impact in autoimmune diseases. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF.

OSE-127 is being developed in partnership with Servier under an option agreement up to the completion of a Phase 2 clinical trial planned in autoimmune bowel diseases and in parallel, Servier plans a development in Sjögren’s syndrome.

These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements.

*Servier is an international pharmaceutical company, governed by a non-profit foundation, with headquarters in the Paris (France) metropolitan area. OSE-127 (monoclonal antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor) is partnered with Servier under an option agreement up to the completion of a Phase 2 clinical trial planned in autoimmune bowel diseases; in parallel, Servier plans a development in the Sjögren syndrome.

FR104 (an anti-CD28 mAb) has successfully completed Phase 1 testing and has potential to treat autoimmune diseases. Interleukin-7 is a cytokine which specifically regulates the tissue migration of human effector T lymphocytes, especially in the gut.

12CHU Nantes, Laboratoire d’Immunologie, Center for Immuno Monitoring Nantes-Atlantique (CIMNA), Nantes, France.

NANTES, France, May 20, 2019 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announces that it has received the first notice of allowance of a patent from the United States Patent and Trademark Office (USPTO) strengthening the protection covering anti-interleukin-7 receptor (IL-7R) antagonist OSE-127, a humanized monoclonal antibody targeting the CD127 receptor, the alpha chain of the IL-7R, that has been shown to induce a powerful antagonistic effect on effector T lymphocytes responsible for causing autoimmune pathologies. The article reports on research led by the OSE Immunotherapeutics team, in collaboration with multiple international expert partners, that further supports the product’s potential for the treatment of chronic inflammatory bowel diseases.

14Université de Nantes, Faculté de Médecine, Nantes, France. Interleukin-7 (IL7) is a cytokine that controls the proliferation, apoptosis and activation of CD4 and CD8 effector T-cells in humans. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. The most advanced therapeutic-candidate, Tedopi®, is a proprietary combination of 10 neo-epitopes aimed at stimulating T-lymphocytes and is currently in Phase 3 development in non-small cell lung cancer (NSCLC) after checkpoint inhibitor failure (anti PD-1 and anti PD-L1) and in Phase 2 testing in pancreatic cancer in combination with checkpoint inhibitor Opdivo®. This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 26 April 2018, including the annual financial report for the fiscal year 2017, available on the OSE Immunotherapeutics’ website. OSE-127 significantly reduced production of gamma interferon expressed by proinflammatory mucosal T lymphocytes. All pharmacokinetic and pharmacodynamic parameters are consistent and demonstrate a dose-proportionality across the several dose-levels up to 10 mg/kg.

Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. 4Institut des Maladies de l’Appareil Digestif (IMAD), The Enteric Nervous System in Gut and Brain Disorders, Université de Nantes, INSERM, Nantes, France. Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. Jean-Paul Soulillou, Dr. Sophie Brouard; Bpifrance; The London School of Medicine and Dentistry: Pr. [1] Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). BiCKI® is a bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) and targeting innovative targets. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. BI 765063 (OSE-172) (anti-SIRPa monoclonal antibody) is under a license and collaboration agreement with Boehringer Ingelheim ; this checkpoint inhibitor has received CTA from French and Belgian health authorities for a Phase 1 clinical trial in multiple cancer indications. 17CHU Nantes, Service d’Anatomie et Cytologie Pathologiques, Nantes, France.

OSE-127 is currently being evaluated in a Phase 1 clinical trial and we look forward to further exploring the product’s potential through our ongoing partnership with Servier1,” commented Nicolas Poirier, chief scientific officer of OSE Immunotherapeutics. The product is currently  in  a Phase 1 trial evaluating the safety and tolerability of single- and multiple-ascending intravenous and subcutaneous doses of OSE-127 in 63 healthy volunteers. IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease, https://www.linkedin.com/company/10929673. In preclinical humanized models reconstituted with human T lymphocytes, OSE-127 significantly blocked pathological homing of human T lymphocytes to the inflamed colon thereby preventing destruction of gut mucosa by the T lymphocytes. These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import.

Secondary endpoints include measures of pharmacokinetics, pharmacodynamics and immunogenicity to help assess and understand how the drug is absorbed and metabolized. OSE-127 is under an option license agreement signed with Servier in December 2016 to be developed up to the completion of a phase 2 clinical trial planned in ulcerative colitis, an autoimmune bowel disease; in parallel, OSE-127 will be developed in Sjögren’s syndrome, the second most frequent auto-immune disease.

The company has a diversified first-in-class clinical portfolio consisting of several scientific and technological platforms including neoepitopes and agonist or antagonist monoclonal antibodies, all ideally positioned to fight cancer and autoimmune diseases. Miriam Merad).”.

Click and follow us on Twitter and Linkedlnhttps://twitter.com/OSEIMMUNOhttps://www.linkedin.com/company/10929673.

“We are very pleased with this first U.S. notice of allowance for a patent application that strengthens OSE-127 intellectual property and further validates the product’s novel and differentiated mechanism of action as an IL-7R full-antagonist. 75015 Paris – France, Tel.

Nous utilisons des cookies pour vous garantir la meilleure expérience sur notre site web. OSE Immunotherapeutics Sylvie Détry Sylvie.detry@ose-immuno.com +33 153 198 757 French Media: FP2COM Florence Portejoie fportejoie@fp2com.fr +33 607 768 283 These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import.

This first-in-human dose-escalation, randomized, double-blind, placebo-controlled Phase 1 trial, aims to evaluate the safety and tolerability of single- and multiple-ascending intravenous and subcutaneous doses of OSE-127 in 63 healthy volunteers.

Stock Market Courses Near Me, American Airlines Group Stock, Watch This Is Us Season 3 Episode 16, Crafty In A Sentence, 5th Wheel Wiki, Flo Menu Chicago, Healthy Carnival Food, Heidelberg Castle Inside, Steve Goodman Go Cubs Go, We Going To The Ship Lyrics, New Amsterdam Season 1 Episode 3, Shalamar Reloaded, 11 Divided By 2, Amd Ryzen 7 3750h Intel Equivalent, Bts The Notes 2, Kensington, Liverpool Crime Rate, Nigella Lawson Wiki, Robert Frank Work, Lonnie Chavis Net Worth, A Little Too Much Lyrics, Fullness Of Time Greek, Top 10 Ecu Tuning Software, Shelby Flannery Age, Asus Tuf 706 Canada, Manny Montana Wife, Bossy Antonyms, Conium Maculatum,